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1. Introduction 
In the U.S. there are over 300,000 people who suffer from spinal cord injuries. This incident 
increases every year by 10,000 to 12,000 new patients (Harrop et al., 2006). In Canada, about 
36,000 people live with spinal cord injuries, while 55% of them, are people in the 
reproductive phase of their life, aged 16-30 years, and the ratio of men to women is 
calculated to 4 /1(Mittmann et al., 2005). For several years there was a myth in societies that 
people with paraplegia or quadriplegia have no sexuality, do not have erectile function and 
that they are infertile. In fact, sexual expression is a component of personality and it is 
independent to the erectile function or fertility status. In handicaps lack of sexual interest is 
associated with social withdrawal and inability to recover while sexual alertness is 
associated with faster and better recovery. The degree of sexual rehabilitation is directly 
related to physical rehabilitation, social integration and quality of life (Biering-Sorensen & 
Sonksen, 2001; Fisher et al., 2002). Last years the medical community emphasizes on quality 
of life and sexuality of people with spinal cord injuries. It is shown that the 66% of patients 
with spinal cord injuries consider their erection sufficient for sexual activity. The incidence 
of injury on the person's sexual function depends on the location and the extent of the 
damage. After Spinal Cord Lesions (SCL), both men and women are reporting decreased 
desire and low frequency of sexual activity (Deforge et al., 2006).  
2. Pathophysiology of Erectile Dysfunction (ED) after SCL 
Erection is a neurovascular phenomenon which takes place under neuro-hormonal control. 
Sensory data from the eyes and skin are relayed to certain areas within the hypothalamus 
where appropriate signals are relayed to the penis. The upper centers which regulate the 
erectile function in the brain are located at the cortex and the hypothalamus, as mentioned 
above. The main involved nuclei are: paraventicular nucleus, medial preoptic area, 
paragigantocellular nucleus, and locus coeruleus. The lower centers are located in the spinal 
cord. These centers are two: the psychogenic, sympathetic erection center which is located at 
the Th11-12 until L2-3 level of spinal cord and the reflexogenic, parasympathetic erection 
center which is located at the S2-4 level of spinal cord. The sympathetic erection center is 
purely autonomous, contains fibers with evoked and others with inhibitory action and 
travels with the inferior hypogastric plexus. The parasympathetic erection center contains 
also somatic fibers. The afferent fibers are coming from the pudendal nerve and the dorsal 
penile nerve, while the efferent fibers involve in the formation of the cavernous nerves and 
the inferior hypogastric and sacral plexus. Sympathetic innervation provides inhibitory 
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pathways whereas parasympathetic and somatic innervations are crucial for erection. The 
two centers of the spinal cord are under the control of the brain (Saenz de Tejada et al., 
2005). 
Erection can be distinguished to reflective and psychogenic according to the origin of its 
induction and the erection center which is mainly involved. Reflective erection is the 
outcome of somatoaesthetic stimulation and may be independent of sexual arousal. This 
erection takes place through the reflexogenic, parasympathetic erection center. Psychogenic 
erection, which predominates in humans, is the result of sexual desire caused by images, 
fantasies and thoughts related to previous sexual experiences. The psychogenic, sympathetic 
erection center is mainly responsible for this kind of erection. The erectile function in 
patients with SCL depends on the location of the injury and the extent of the lesion. In 
patients with upper cord lesions, reflexogenic erections are preserved in 95% of them, while 
in patients with complete lower cord damages this rate is only 25%. The quality of erection 
is better as higher the lesion is located (Eardley & Kirby, 1991). Derry et al., in their study are 
reporting that 25% of men with SCL regain their erectile function one month after injury, 
when 60% and 80% regain their erections in a period of six months and one year 
respectively after injury (Derry et al., 2002). The preservation of the sacral parasympathetic 
neurons leads to the maintenance of reflexogenic erection. In case of sacral injury 
thoracolumbar pathway may take over through synaptic connections. In general, men with 
cervical and thoracic lesions regain their erections sooner and better than men with lumbar 
lesions (Courtois et al., 1993). 
Reflexive erections, which require the integrity of parasympathetic erectile center (S2-4), 
have been observed in people with SCL. These arise after irritation of the skin or mucosa 
below the level of the lesion. Manipulations such as rubbing of the thighs or nipples, 
squeezing of the glans, suprapubic percussion, irritation of the anal region, proved to be 
more effective than masturbation or any other stimulation of the genitalia (Saenz de Tejada 
et al., 2005; Derry et al., 2002). Lesions higher to Th11 level are combined with erection of 
both corpora cavernosum and corpus spongiosum, while lesions below this level exclude 
the participation in the erection of the corpus spongiosum (Biering-Sorensen & Sonksen, 
2001). This erection is usually sufficient for penetration, but it has short duration. The 
reflexive erections maintain in 95% of patients with total damage over the sacral center, 
while in lower level lesions this percentage is up to 25%. The training for the challenge of 
this reflex is part of the sexual rehabilitation. 
Psychogenic erections have been observed in 60% of patients with intact sympathetic 
erectile center (Th11-L2) and lesion below the L2 level. Psychogenic erections, as mentioned 
above, are independent from direct physical stimulation and are the result of visual or 
acoustic stimuli, dreams, fantasies or memories. These erections are usually with low quality 
and short duration. Objectively, it is more of a swelling of the penis rather than a hard 
erection, rarely allowing penetration (Derry et al., 2002; Courtois et al., 1999; Smith & 
Bodner, 1993; Chapelle et al., 1980). 
Mixed erection occurs when the SCL is between the two centers. These erections onset after 
a psychic stimulus and maintain or even are enhanced by a physical stimulus, or they are 
prolonged reflecting erections which are enhanced by a strong sexual desire. 
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Nocturnal erections have been also recorded in men with SCL. These erections usually take 
place during the REM phase of the sleep. The comparison between the erections of 
quadriplegic and paraplegic patients showed that quadriplegic men had better erections 
(regarding hardness and duration) than paraplegic patients. Additionally, thoracic spinal 
lesion was associated with poor nocturnal erections comparing with cervical spinal injuries 
(Suh et al., 2003). 
Patients with lesions above the Th6 level often present the phenomenon of autonomous 
dysreflexia, which involves reflecting increased sympathetic tone at the level below the 
lesion. This increased sympathetic response causes vasoconstriction and hypertension. At 
the levels higher to the spinal lesion, vasodilatation takes place and causes flashing and 
headache. The more serious symptom is the parasympathetic activation which decreases the 
heart rate. This situation with excessive hypertension and bradycardia is dangerous for the 
patient and it was found that sexual arousal may trigger dysreflexia. In these cases sexual 
activity must be avoided (Rossier et al., 1971; Frankel & Mathias, 1980). 
3. Diagnostic approach to patients with SCL 
3.1 Sexual history 
Sexual history is the first step in the evaluation of patients with ED. Our purpose is to assess 
the pre-injury and the post-traumatic sexual function and to identify the ED. The absence or 
presence of erections, under what circumstances they took place, the number and the 
frequency of them, the quality of erections (regarding hardness and duration) compared 
with the erectile function before injury and the frequency of sexual intercourse, are some of 
the questions which have to be answered. Additionally, a good history will assess the 
mental and psychological status of individuals whereas ED with psychogenic origin 
described in 10% of men with SCL (Monga et al., 1999; Tay et al., 1996). 
3.2 Physical examination and laboratory tests 
Physical examination reveals clinical signs which contribute to the diagnostic approach of 
ED. During the examination of the external genitalia, neurological examination should also 
be included. Our aim is to identify the level of lesion, according the sacral and the thoracic-
lumbar origin of the neurosis of external genital organs. Assess of the sensation of the 
genitalia, the perineum and the perianal region as well, is essential for the evaluation of 
parasympathetic erectile center, as the somatic-sensation of these areas reflects to the S2-4 
level of the spinal cord. By evaluating the reflex of the cremaster muscle, we can assess the 
S1-2 reflex arc. By evaluating the reflexes of rectus muscles, we can assess the Th9-12 reflex 
arcs and the bulbocavernous reflex is suitable to investigate the integrity of S2-4 reflex arc 
(Vodusek, 2003). Additionally, tendon reflexes of the lower limbs can evaluate the lumbar 
region of spinal cord. 
Apart from control of reflexes, the use of specific neurological tests has been reported in the 
literature. The measurement of latency time of the bulbocavernous reflex by placing 
electrodes on the penis and the bulbocavernosal muscles and the measurement of 
somatosensory cortical evoked potentials by placing electrodes on the scalp, may give an 
accurate assessment of the nervous lesions (Bird & Hanno, 1998). 
www.intechopen.com
 Erectile Dysfunction – Disease-Associated Mechanisms and Novel Insights into Therapy 
 
130 
3.3 Nocturnal Penile Tumescence and Rigidity (NPTR) 
The recording of nocturnal erections in normal subjects is a method for the differential 
diagnosis of psychogenic from organic erectile dysfunction. The recording of these erections, 
usually during REM phases of sleep, is made by the Rigiscan (Fig. 1). Rigiscan uses two 
inflatable rings which are adapted at the base and at the tip of the penile shaft. These rings  
work as sensors for the increase in the diameter (tumescence) and the hardness during 
erection. The duration and the quality of these erections represent the erectile capacity of the 
patient. The findings must be confirmed for at least two nights. 
 
Fig. 1. Rigiscan device uses two inflatable rings which act as transducers in order to study 
the tumescence and the rigidity during erectile episodes. 
Rigiscan studies have shown that the onset of erection does not appear to require intact 
pathways from the brain towards the spinal cord, while nocturnal erections were observed 
in men with complete SCL (Suh et al., 2003). Rigiscan studies showed that men with SCL do 
suffer from psychogenic ED at a rate of up to 10% (Tay  et al,. 1996). 
3.4 Dynamic Doppler Ultrasound Evaluation 
Dynamic Color Doppler ultrasound tomography is a method which can evaluate the 
vascular potential of the corpora cavernosa and can assess the hemodynamic of the penis. 
After the administration of vasoactive drugs (intracavernousal injection of alprostadil 10μg), 
blood flow is studied by measuring the peak-systolic and the end-diastolic velocity (Fig.2). 
According to these findings, vascular etiology (low arterial inflow or venous escape 
syndrome), of erectile dysfunction can be identified. 
In cases of neurogenic ED, ultrasound findings are usually normal, as the majority of these 
patients, is young with no vascular pathology. If a reduced blood supply of the cavernous 
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artery is present, probably this occurs due to concomitant vascular inefficiency (Kim et al., 
2006). Normal reply to vasoactive drugs is described in 80% of patients with SCL, while 
there are some other studies which record high rates of vascular lesions in these patients 
(Robinson et al., 1987). 
 
Fig. 2. Color Doppler ultrasound, 10 minutes after intracavernousal injection of 10 μg 
alprostadil. Due to high End-Diastolic Velocity (EDV) this is an image of venous escape 
syndrome. 
4. ED treatment in men with SCL 
The treatment of ED in paraplegic or quadriplegic patients follows the therapeutic strategy 
of any other case of organic ED. According to that, we can apply stepped treatment of 1st, 2nd 
and 3rd line. The 1st line of treatment includes oral inhibitors of phosphodiesterase type 5 
(PDE-5) and vacuum devices. In the 2nd line of treatment there are penile injections and 
transurethral application of vasoactive substances. Finally, in the 3rd line of treatment option 
there is the implantation of penile prosthesis (Ramos & Samso, 2004). Patients should be 
informed about all the treatment options from the beginning of the therapy, although the 
treatment is applied step by step. This is very important for neurogenic patients in order to 
be optimistic for the outcome of the treatment. General considerations regarding blood 
pressure, lipid profile, hormonal status, diabetes mellitus and stop smoking are necessary to 
all patients with ED. On the other hand, most of the patients with SCL are young men with 
excellent sexual function before injury and the etiology of their ED is mostly neurogenic. In 
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these patients psychogenic component is present sometimes and other organic causes, 
vascular inefficiency for example, occur rarely. 
4.1 First line treatment 
4.1.1 Oral treatment 
Since sildenafil gained the approval of use, it has proved its efficiency against ED, of any 
organic reason. The efficacy and its safety have been demonstrated in studies in patients 
with SCL. In bibliography there are two relevant, randomized, prospective, multicenter 
placebo controlled studies. Giuliano et al. studied 178 patients with SCL and indicated 76% 
efficacy of sildenafil compared with 4% of placebo (Giuliano et al., 1999). In another similar 
study by Maytom et al. (with only 27 patients) it was referred efficacy in sildenafil 65% vs. 
8% in placebo (Maytom et al., 1999). In the same study the overall satisfaction with their 
sexual activity reported in 75% in the sildenafil group compared with 7% in the placebo 
group. In a meta-analysis of eight other studies it was indicated the overall effectiveness of 
sildenafil in 80% of these patients (Deforge et al., 2006). Derry et al. reviewing the literature 
indicates that the proportion of patients with SCL showing improvement in their erectile 
function reaches 94%. The majority of them (72%) indicate successful sexual intercourse, as 
well. Response rates were generally higher in patients with partial section of the spinal cord 
(incomplete lesions). However, a significant proportion of patients with complete cross-
section, regardless of the location of the lesion, benefited from the administration of 
sildenafil (Derry et al., 2002; Sanchez Ramos et al., 2001). The existing literature, thus, 
demonstrates high efficacy and safety of oral treatment with sildenafil in patients with ED 
after SCL. 
There are at least two studies in the literature supporting the efficacy of vardenafil in the 
treatment of ED for patients with SCL. Giuliano et al. in a multicenter, double-blind and 
placebo controlled study, with duration of 12 weeks, which included 418 patients, reported 
erections, sufficient for penetration in 76% of patients in the vardenafil group, compared 
with 41% of patients in the placebo treatment group (Giuliano et al., 2006). In the same 
study, 59% of the vardenafil group indicated satisfactory duration of erection, compared to 
22% of the placebo group. Another open label study, without control, dealing with 
vardenafil administration in SCL patients, based on 38 patients, indicated achievement of 
erection, efficient for penetration in 83% of patients and duration of erection satisfactory for 
88% of those (Kimoto et al., 2006). 
Regarding tadalafil, there is a comparative study by Del Popolo et al. between sildenafil and 
tadalafil in patients with ED and SCL (Del Popolo et al., 2004). This was a randomized, 
blind; cross-over study with 15 patients in each arm and duration of 12 weeks. The study 
indicated that tadalafil allowed to the majority of patients to achieve a satisfactory erection 
for up to 24 hours after the administration of the drug, but this was due to pharmacokinetic 
of tadalafil. Additionally, an improvement of sexual satisfaction of both patients and their 
sexual partners has been recorded in both groups (sildenafil and tadalafil). In another 
multicenter, randomized, placebo-controlled study by Giuliano et al. was reported statistical 
significant improvement, to the tadalafil group, at the erectile function domain of the IIFF 
questionnaire and at the questions 2 and 3 of the Sexual Encounter Profile (SEP) which 
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regards the achievement of sufficient erection and satisfactory intercourse (Giuliano et al., 
2007). These findings were confirmed by another study by Lombardi et al., that reported 
improvement at the IIFF score and at the ability to achieve an efficient erection (SEP 2) and a 
satisfactory intercourse (SEP 3), in patients with SCL after the appropriate dose of tadalafil 
(Lombardi et al., 2008). 
There is a comparative study of all PDE-5 inhibitors in patients with SCL which was 
published in 2007 (Soler et al., 2007). The study consisted of three groups of patients, 
according the PDE-5 inhibitor which was used. In the group of sildenafil there were 120 
patients, in the group of vardenafil there were 66 patients and in the group of tadalafil there 
were 54 patients. Initially all patients received the lower dose of each drug and there was 
dose up regulation until the efficacy was sufficient. The overall efficacy was similar for all 
the drugs (85% for sildenafil, 74% for vardenafil and 72% for tadalafil). The duration of 
erections was also similar for all (26 - 34 minutes).  The higher dose of the drug required in 
45% in the group of sildenafil, compared with over 70% of the patients in the other two 
groups. In another meta-analysis of 18 studies, regarding PDE-5 inhibitors in men with SCL 
was reported statistical significant improvement of erectile function compared to placebo in 
11 studies (Lombardi et al., 2009). The overall amount of patients was 705 in sildenafil, 305 
in vardenafil and 224 in tadalafil. Only 15 patients stopped treatment due to adverse events. 
This meta-analysis came to the conclusion that the relatively small amount of patients and 
the different methodology of the studies do not allow reliable comparisons between the 
drugs. On the other hand, there is enough data in the literature supporting that PDE-5 
inhibitors are safe and effective treatment option for the ED of men with SCL. 
4.1.2 Vacuum devise 
The use of vacuum device is an alternative treatment option for the ED of people with SCL, 
with satisfactory efficacy (Zasler & Katz, 1989; Heller et al., 1992). The vacuum device is a 
cylinder with an open edge. The penis is placed through the open edge inside the device 
and by pumping; vacuum is created inside the cylinder. The negative pressure forces the 
blood to fill the corpora cavernousa, causing erection. After erection a ring which is placed 
tight around the base of the penis is necessary for the maintenance of the erection (Fig. 3). 
Efficacy and complications of these devices were studied in 20 patients and their partners 
(Denil et al., 1996). After 3 months of use, 93% of men and 83% of women reported erections 
sufficient for vaginal penetration which lasted for about 18 minutes. After 6 months, 
however, only 41% of men and 45% of women were satisfied with the use of vacuum device. 
The most unpleasant fact was the early loss of the rigidity of the erection. Overall, 60% of 
men and 42% of women reported improvement in their sexual lives by using the vacuum 
device. Finally, adverse effects such as bruising or swelling and even gangrene of the penis 
have been recorded (Rivas & Chancellor, 1994). The higher complication rate of vacuum 
device in men with SCL has to do with the absence of sensation in the area, so a very tight 
ring remaining for a long time can cause tissue ischemia and necrosis without any pain or 
disturbance. The appropriate advice for the people using the device is to be careful with the 
overall use and to avoid the very high negative pressure and the long-lasting strangle of the 
penile shaft. 
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Fig. 3. The vacuum device is a cylinder with an open edge. The penis is placed through the 
open edge inside the device and by pumping; vacuum is created inside the cylinder. 
4.2 Second line treatment 
4.2.1 Intracavernousal injections of vasoactive substances 
Men with ED after SCL respond very well to intracavernousal injections of vasoactive 
substances (Hirsch et al., 1994; Deforge et al 2006). This happens, because most of these 
people are young, with small likelihood of an additional vascular disease. The technique is 
simple and relatively painless. The high effectiveness of the injections in combination with 
the absence of sensation at the penis makes this choice friendlier to paraplegics. The 
injection takes place between the 1st and 3rd or between the 9th and 11th hours of the penile 
shaft (Fig. 4). A gentle massage of the area helps the drug to be absorbed. The erection 
begins five to ten minutes later and it is independent from any sexual arousal. 
Most studies report high rates, which reach 95% response to vaso-active substances such as 
papaverine and alprostadil (Lebib Ben Achour et al., 2001; Dietzen & Lloyd, 1992). Side 
effects and complications described in the literature are: priapism, skin bruises and 
cavernosal fibrosis. Papaverine is responsible for higher rates of priapism and fibrosis than 
alprostadil. Patients with SCL develop priapism more often, maybe due to excessive release   
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Fig. 4. The injection takes place between the 1st and 3rd or between the 9th and 11th hours of 
the penile shaft, after penile stretching. 
of neurotransmitters which promote erection or due to sympathetic hypertonia. For these 
reasons in the beginning of the treatment lower doses of vasoactive drugs are used and the 
dose is entitled for each patient. In a meta-analysis of other studies, there was an overall rate 
of men with satisfactory erections reaching the 90% of the users of intracavernousal 
injections (DeForge et al., 2006). In another study there was a comparison between the use of 
vacuum device and the administration of injections of papaverine (Chancellor et al., 1994). 
Eighteen men with SCL participated in this study, which was cross-over designed. After 
both treatment options, half of the patients chose injections and half of them chose vacuum 
device. 
4.2.2 Urethral administration of vasoactive substances 
The communication between the corpora cavernosa and the corpus spongiosum was the 
base for the intra-urethral application of vasoactive drugs. Alprostadil (PGE1) has been used 
for this purpose. The way of action is the same to intracavernousal injections, without 
needles and punctures. There is an applicator which places the drug into the urethra (Fig. 5). 
The overall efficacy rate is reported at 65.9% of 995 men with ED (Padma-Nathan et al., 
1997). 
In patients with SCL the outcome was not as satisfactory as using intracavernousal 
injections (Bodner et al., 1999). Regarding adverse events, systemic absorption of alprostadil 
was responsible for hypotensive episodes. The use of a tight ring at the base of the penis is 
essential in order to avoid this rapid absorption and to maintain the achieved erection. 
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Fig. 5. For the intra-urethral placement of alprostadil a specific applicator is used. 
4.3 Third line treatment 
The implantation of penile prosthesis is the 3rd line treatment and represents the surgical 
option for the management of ED. The prosthesis can be malleable or hydraulic. Hydraulic 
one may consist of two or three pieces (Fig. 6). The application of penile prosthesis in men 
with SCL accompanied with a high rate of complications, as it was indicated in some older 
studies (Dietzen & Lloyd, 1992). In these series it was reported mechanical damage in 43%, 
infection in 37%, erosion in 10% and hematoma 7% of patients. An overall complication rate 
of 13.3% was also reported in another study (Kimoto & Iwatsubo, 1994). 
As the prosthesis models become more contemporary the results improve as well. In a 
relatively recent study a total number of 245 patients with SCL participated (Zermann et al., 
2006). Apart from the restoration of erectile function, penile prosthesis implantation offered 
a wide enough penis in order to achieve a better fixation of a condom catheter. Regarding 
erectile function, 82.6% of men and 67.5% of their sexual partners reported the treatment as 
successful. Complication rate was lower than in older studies. It was reported infection in 
5%, and erosion from 0 to 18% depending on the type of prosthesis (none for the three 
pieces inflatable ones and 18% for the malleable types). In a meta-analysis based on five 
previous studies where prostheses were implanted in patients with SCL, serious 
complications were reported in 10% of the cases. On the other hand, patients who 
experienced no complications were very satisfied (Deforge et al., 2006; Xuan et al., 2007). 
The higher complication rate which is reported in paraplegics, compare to ambulant, 
impotent patients probably has to do with the absence of sensation which may lead to 
excessive use of the prosthesis which is compressing the glans and the other tissues, causing 
ischemia. This is the first step for erosion. Generally speaking, a penile prosthesis improves 
the quality of life of patients with SCL significantly; however, erosion and infection are still 
remarkable problems. 
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Fig. 6. On the left: a malleable prosthesis (one of the two cylindrical pieces); on the right: a 
three pieces inflatable prosthesis with some of additional tips. You can distinguish the 
cylinders, the pump and the reservoir.  
5. Therapeutic strategy  
The accurate diagnostic for SCL is crucial for choosing an adequate treatment. The level, the 
extension and the total or partial character of the neural damage may drive to one or other 
treatment option. Generally, patients with partial section of the spinal cord will respond 
better to oral or topical treatments. It has been also proven that oral pharmacotherapy with 
PDE-5 inhibitors is more effective if at least one of the erection centers has maintained. At 
the begging, PDE-5 inhibitors were used in patients with intact S2-4 reflex arc, which 
indicated the integrity of parasympathetic erection center. Later on, it was found that this 
kind of pharmacotherapy is also effective in patients who did not appear any spontaneous 
erectile function. In general, patients with lesions at higher levels respond better to oral 
therapy. 
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The use of vacuum device and penile injections require skill on behalf of the patients. 
Tetraplegic patients face more difficulties in the appliance of these therapies, which are 
possible only by the partner’s contribution. If the patient is a condom catheter user due to 
incontinence, penile prosthesis may offer a solution for both erectile dysfunction and 
incontinence, by supporting a better fixation of the condom catheter. 
In our center we use an algorithm for the management of ED in paraplegics. This is 
described below: If the patient has residual (spontaneous or induced by sexual arousal) 
erection, which is, in general, not sufficient for vaginal penetration, vacuum device and/or 
oral pharmacotherapy with PDE-5 inhibitors are offered. If the patient is not satisfied we 
apply intracavernousal injections of vasoactive drugs, alprostadil in most cases. At this point 
the majority of our patients is satisfied. In cases that there is fibrosis of the cavernosal tissue, 
usually after recurrent priapism episodes, penile prosthesis remains the only reliable choice 
for the management of the ED of these men. The implantation of the penile prosthesis is the 
ultimate therapeutic option with excellent results. Finally, it has to become clear to all 
patients that the above treatment options are suitable for the ED and do not solve the 
ejaculation or/and orgasm disorders they might experienced. 
The role of sexual partner is very important as the partner must be part of the therapeutic 
option. The couple has to “open its mind” regarding the sexual activity. They must 
compromise, at the beginning, and finally, regulate their sexual lives in a status that 
penetration is not the main sexual activity. 
6. Conclusion 
Men with paraplegia suffer from sexual dysfunction which impacts the quality of their life 
and affects their partners. ED, possible absence of orgasm and infertility are conditions 
related to paraplegia. Patients with SCL face neurogenic ED. Erection is a neurovascular 
phenomenon which takes place under neuro-hormonal control. Any lesion at the involved 
neural pathways is responsible for this dysfunction. On the other hand the vascular element 
of the erection is, in general, healthy. According to these principals, the treatment strategy is 
designed and applied. No therapeutic method is efficient and suitable for all patients. 
Treatment must follow the wishes, the mental level and the skills of the patient according 
the needs of the couple. 
The physicians who treat paraplegic patients must take these conditions into consideration. 
A team work by rehabilitation doctors, urologists and psychiatrics is needed for the optimal 
treatment option.Sexual rehabilitation targets in neuromodulation using voluntary release 
of a reflex erection attempting to use this erection for sexual purpose. This is possible 
through stimulation of the skin or mucosa below the level of the lesion. If a trigger point 
which promotes an erection is identified, patient has to get familiar with the onset of this 
reflex in order to use it during sexual activity. 
Treatment options like PDE-5 inhibitors, vacuum devices, intracavernousal injections or 
intra-urethral administration of vasoactive medications and penile prosthesis are in 
specialist’s armament for the treatment of erectile dysfunction in men with paraplegia.The 
oral treatment with PDE-5 inhibitors is effective in the majority of paraplegic patients. 
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Vacuum device is a reliable treatment option with some restrictions. The most effective 
conservative treatment is the intracavernousal injection of vasoactive drugs, as the erectile 
dysfunction is not caused by vascular inefficiency. Urethral application of vasoactive drugs 
is less effective and is associated with high incidence of hypotension. The implantation of 
penile prosthesis remains the most effective treatment option, which is associated with a 
relatively high rate of complications (~10%) in this population (Deforge et al., 2006). Sexual 
rehabilitation remains very important for the physical rehabilitation and the active return of 
these people to the society. 
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